1. Home
  2. NVCR vs TBBK Comparison

NVCR vs TBBK Comparison

Compare NVCR & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TBBK
  • Stock Information
  • Founded
  • NVCR 2000
  • TBBK 1999
  • Country
  • NVCR Switzerland
  • TBBK United States
  • Employees
  • NVCR N/A
  • TBBK N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TBBK Major Banks
  • Sector
  • NVCR Health Care
  • TBBK Finance
  • Exchange
  • NVCR Nasdaq
  • TBBK Nasdaq
  • Market Cap
  • NVCR 1.9B
  • TBBK 2.4B
  • IPO Year
  • NVCR 2015
  • TBBK 2004
  • Fundamental
  • Price
  • NVCR $17.60
  • TBBK $63.08
  • Analyst Decision
  • NVCR Buy
  • TBBK Buy
  • Analyst Count
  • NVCR 7
  • TBBK 3
  • Target Price
  • NVCR $32.43
  • TBBK $65.33
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • TBBK 538.1K
  • Earning Date
  • NVCR 07-24-2025
  • TBBK 07-24-2025
  • Dividend Yield
  • NVCR N/A
  • TBBK N/A
  • EPS Growth
  • NVCR N/A
  • TBBK 20.50
  • EPS
  • NVCR N/A
  • TBBK 4.42
  • Revenue
  • NVCR $621,711,000.00
  • TBBK $502,282,000.00
  • Revenue This Year
  • NVCR $5.56
  • TBBK N/A
  • Revenue Next Year
  • NVCR $9.19
  • TBBK $6.71
  • P/E Ratio
  • NVCR N/A
  • TBBK $14.29
  • Revenue Growth
  • NVCR 18.27
  • TBBK 10.02
  • 52 Week Low
  • NVCR $14.17
  • TBBK $40.51
  • 52 Week High
  • NVCR $34.13
  • TBBK $65.84
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • TBBK 76.14
  • Support Level
  • NVCR $16.81
  • TBBK $55.58
  • Resistance Level
  • NVCR $18.59
  • TBBK $63.70
  • Average True Range (ATR)
  • NVCR 0.74
  • TBBK 1.99
  • MACD
  • NVCR 0.08
  • TBBK 0.71
  • Stochastic Oscillator
  • NVCR 56.18
  • TBBK 95.13

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

Share on Social Networks: